StemCell Therapy

Banking Teeth for Stem Cell Therapy

Banking baby teeth or wisdom teetha practice thats been around for about 10 yearsis becoming more widely accepted in developed areas of the world, according to researchers. It involves cryopreserving teethand the dental stem cells they containfor potential stem cell therapy in the future.

Most research surrounding dental stem cells and tooth banking is still in the experimental stage and, at this time, scientists disagree about whether its worthwhileunlike cord blood banking, which has proven benefits for stem cell therapy. Some research suggests preserved dental stem cells could one day be used to regenerate healthy tissue and help fight complex diseases. But many experts remain less convinced of the potential benefits, as so much of the research is preliminary.

So far, the research has centered around dentinthe innermost hard layer of the tooth, below the enameland soft tissue beneath the dentin called pulp. The pulp contains the tooths nerve and blood supplies. In studying how teeth repair themselvesfrom a cavity, for exampleresearchers discovered that teeth contain stem cells. More studies are needed to determine if these dental stem cells can be harvested, preserved, stored, and someday used for stem cell therapy.

Image Credit: iStock

Sourced from: CNN

A new study suggests that cardiovascular decompensationa life-threatening drop in blood pressure caused by serious injuries involving significant blood lossmay be treated temporarily at the scene or during transport to the hospital simply by applying a bag of ice water to the injured persons face. Decompensation, which remains a dangerous complication even after bleeding has stopped, reduces the delivery of oxygen to the brain, heart, and other vital organs.

For the study, ten healthy volunteers were placed in a special chamber that simulates blood circulation after a person has lost one-half to one liter of blood and a tourniquet has been applied to stop the bleeding. Researchers applied bags of ice water or bags of room-temperature water to the study participants faces for 15 minutes while they continuously monitored cardiovascular function. They discovered that participants treated with bags of ice water experienced significant increases in blood pressure, suggesting that applying ice water can improve cardiovascular function after blood loss and prevent a dangerous drop in blood pressure.

Researchers expect to begin clinical trials soon. The hope is that this simple technique can be used by first responders or medics in the field of combat to improve survival rates after injuries involving blood loss by providing extra time for transport to a hospital or other medical facility.

Image Credit: iStock

Sourced from: ScienceDaily

Cooking dinner at homerather than eating outis a good way to eat healthier and save money, according to researchers at Oregon State University and the University of Washington. Historically, people with a higher socioeconomic status are generally healthier than those with lower incomes, but this study suggests otherwiseIF more money means dining out more often and less money means eating at home.

The study involved about 400 adults in the Seattle-area. Study participants were surveyed about their cooking and eating behaviors for one week and provided various socioeconomic information. Their weekly food intake was graded using the Healthy Eating Index (HEI)a scale that ranges from 0 to 100, with higher scores indicating a healthier diet.

According to researchers, cooking at home three times per week produced an average score of about 67 on the Healthy Eating Index, and cooking at home six times per week resulted in an average score of 74. Results of the study suggest that home-cooked dinners are associated with a diet lower in calories, sugar and fat, overall than dining out regularly.

Image Credit: iStock

Sourced from: Oregon State University

Daily Dose Index

See the original post:
Banking Teeth for Stem Cell Therapy - HealthCentral.com

Wenn

Singer-turned-TV personality Kelly Osbourne wants to help cure fellow Lyme disease sufferers by making stem cell therapy available for all in the U.S.

Ozzy and Sharon Osbournes daughter contracted the condition after she was bitten by a tick during a party for the rockers 56th birthday back in 2004, when her mother had a reindeer sanctuary installed at their Los Angeles home.

However, Kelly wasnt properly diagnosed until 2014, months after suffering a seizure while filming an episode of E!s Fashion Police show in 2013, when doctors claimed her collapse had been caused by epilepsy.

She did some research into her ailments and discovered she was actually struggling with Lyme disease, and promptly sought out alternative treatment to help her overcome the illness.

I started to actually do the one thing doctors tell you not to do and thats to go online and look it up, she explained on Good Morning America, and all roads pointed to Lyme disease so I found a doctor through my mum.

I went to Frankfurt, Germany, and I did stem cell (therapy) and I got cured, Kelly claimed.

The 32-year-old is lucky to have been in a position to afford the treatment, which involves the transplant of stem cells to heal those damaged by the disease, and now she is looking to get involved in making the therapy more widely available and affordable to others less fortunate.

It sickens me that thats not available to everyone and that you have to be considered lucky or privileged to get that sort of treatment, she said. I want to make sure and I will do anything that I can do to make sure that that treatment is available in this country.

Kelly details her experience with the bacterial infection in her new memoir There Is No F**king Secret: Letters from a Bada** B**ch. She isnt the only celebrity to open up about her struggles with Lyme disease pop star Avril Lavigne, and veteran model Yolanda Hadid and her runway star kids Bella and Anwar Hadid have also been battling the illness.

See the original post:
Kelly Osbourne Campaigning to Make Stem Cell Therapy Affordable ... - Hollywood.com

25th Apr 17 | Entertainment News

Singer-turned-TV personality Kelly Osbourne wants to help cure fellow Lyme disease sufferers by making stem cell therapy available for all in the U.S.

Ozzy and Sharon Osbourne's daughter contracted the condition after she was bitten by a tick during a party for the rocker's 56th birthday back in 2004, when her mother had a reindeer sanctuary installed at their Los Angeles home.

However, Kelly wasn't properly diagnosed until 2014, months after suffering a seizure while filming an episode of E!'s Fashion Police show in 2013, when doctors claimed her collapse had been caused by epilepsy.

She did some research into her ailments and discovered she was actually struggling with Lyme disease, and promptly sought out alternative treatment to help her overcome the illness.

"I started to actually do the one thing doctors tell you not to do and that's to go online and look it up...," she explained on U.S. breakfast show Good Morning America, "and all roads pointed to Lyme disease so I found a doctor through my mum.

"I went to Frankfurt, Germany, and I did stem cell (therapy) and I got cured," Kelly claimed.

The 32-year-old is lucky to have been in a position to afford the treatment, which involves the transplant of stem cells to heal those damaged by the disease, and now she is looking to get involved in making the therapy more widely available and affordable to others less fortunate.

"It sickens me that that's not available to everyone and that you have to be considered lucky or privileged to get that sort of treatment," she said. "I want to make sure and I will do anything that I can do to make sure that that treatment is available in this country."

Kelly details her experience with the bacterial infection in her new memoir There Is No F**king Secret: Letters from a Bada** B**ch. She isn't the only celebrity to open up about her struggles with Lyme disease - pop star Avril Lavigne, and veteran model Yolanda Hadid and her runway star kids Bella and Anwar Hadid have also been battling the illness.

WENN Newsdesk 2017

Go here to see the original:
Kelly Osbourne campaigning to make stem cell therapy affordable in ... - TV3.ie

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:
Global Stem Cell Therapy Market - Analysis, Technologies and ... - PR Newswire (press release)

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global Stem Cell Therapy Market 2017-2021" report to their offering.

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the sales of stem cell therapy products/segments in the market.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

Further, the report states that one of the major factors hindering the growth of this market is stringent regulatory environment affecting the product approvals. Gaining regulatory approval is often difficult, unpredictable, and subjective. Stem cell therapy must undergo a broad range of stringent regulations before approval and commercialization. Currently, the US FDA has approved very few products for stem cell therapy.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/ld455v/global_stem_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005786/en/

View post:
Global Stem Cell Therapy Market Growth at CAGR of 36.52%, 2017 ... - Yahoo Finance

Skiing in Aspen, Sean Fair mistimed a landing and felt a shooting pain in his right knee as he crumpled into the snow. He had to slide down the steep slope on his left ski. The doctor revealed that Fairs agony originated from a quarter-sized hole in the cartilage of his knee.

For an active person like Fair, traditional surgery options, like a total knee replacement, restrict motion and are less than ideal. Advances in experimental cartilage repair stem cell treatments, however, now offer new opportunities for young patients to preserve mobility, that defining value of youth.

Fair played football, among other sports, in high school. He played tennis in college and continued to play until he had his ski incident at the age of 31.

All of a sudden, not being able to do anything, I felt 80, he said. All my friends would play tennis together but I would have to sit back and watch.

Sean Fair was diagnosed with OCD, or osteochondritis dissecans. This condition typically develops in teenagers but doesnt usually present symptoms until adulthood when the joint experiences some form of trauma. OCD lesions involve holes, cracks, or loose articular cartilage in a joint.

Fair met with Dr. Andreas Gomoll, an orthopedic surgeon at the Brigham and Womens Hospital in Boston. They discussed knee replacement surgery, microfracture surgery and the possibility of using healthy cartilage from a cadaver donor.

Knee replacement surgery for patients as young as Fair often results with low satisfaction. People who receive the standard metal and plastic knee replacement are functionally limited and face unexpected physical challenges when it comes to activities more intense than a walk. Microfracture surgery would be better, but Fairs injury was too large for that to be practical. Fair and Gomoll decided to wait for a cadaver donor. While waiting, however, Fair joined a clinical trial to test a new approach that would fill the gap in his cartilage with stem cells.

Stem cells can be thought of as undecided cells. Theyre mostly present in embryos and neonates, but they are also found in adults as well. Given the correct environment, and depending on the type of stem cell, they can become more specific cells, like muscle cells or cartilage-forming cells. In Fairs case, Gomoll used donated umbilical cord stem cells from healthy babies delivered in the US. Umbilical cord stem cells are useful because they are able to morph into cartilage-forming cells, they dont require the destruction of an embryo and they have immunosuppressive properties that wouldnt cause Fairs body to reject them.

Anatomical representation of the human knee.

The procedure looked simple. Gomoll made a vertical incision in Fairs kneecap, cutting through the skin and the yellow fat to expose the white cartilage. Gomoll used stainless steel tools to clamp open the incision, while he used a metal ring spanner to scrape the edges of the cartilage pothole. (Picture using a spoon to carve a hole in a large eraser.) Next, the surgeon drilled seven coffee stirrer-sized holes into the bone at the bottom of the quarter-sized pothole. He injected the clear stem cell gel into each coffee stirrer-sized hole and then filled the quarter-sized hole up to its edges with the rest of the stem cell gel. Gomoll smoothed down the stem cell gel like icing on a cake. Then he sutured the wound closed.

Fair wasnt quick to start walking right after the procedure. His knee needed to heal and then he would have to follow a strict rehabilitation process of weekly physical therapy sessions.

Months after his surgery, the stem cells in Fairs knee developed into chondrocytes, cells that secrete a matrix of cartilage, and sealed the pothole in Fairs knee. As of now, Fair is thankful for his treatment. His right knee has healed, but hes still not at 100 percent.

My other knee unfortunately, because of all the issues the [right knee] had, also needs reconstruction, Fair said. Ive got to be careful when I carry my two-and-half-yearold down the steps. Functionally I can walk. I can chase him. I can outrun him, still. Other than that, its not a lot of peripheral movement I can do yet.

According to Gomoll, about 15 other Americans have received the same experimental treatment as Fair. Before this therapy can be offered at any hospital in the US, the clinical trial must obtain FDA approval after proving its efficacy with a larger, more randomized sample of patients. But Gomoll doesnt seem too worried. He says hundreds of patients in South Korea have already undergone the same procedure. Getting there will take some time and money; running comprehensive trials is expensive. Once the procedure is approved, Gomoll imagines thousands of cartilage damaged patients like Fair would potentially be treated with stem cells in the United States.

Go here to read the rest:
Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage - BU News Service

Treatment

The Stem Cell treatment performed at our clinics is a painless medical procedure where Stem Cells (cellular building blocks) are usually administered intravenously and subcutaneously (under the skin). The whole procedure takes approximately one hour and has no known negative side effects.

Following the treatment, the Fetal Stem Cells will travel throughout the body, detecting damaged cells and tissue and attempts to restore them. The Fetal Stem Cells can also stimulate existing normal cells and tissues to operate at a higher level of function, boosting the bodys own repair mechanisms to aid in the healing process. These highly adaptive cells then remain in the body, continually locating and repairing any damage they encounter.

As with any medical treatment, safety should be of the highest priority. The Stem Cells used in our treatment undergo extensive screening for possible infection and impurities.

Utilizing tests more sophisticated than those regularly used in the United States for Stem Cell research and transplant. Our testing process ensures we use only the healthiest cells to enable the safest and most effective Fetal Stem Cell treatment possible. And, unlike other types of Stem Cells, there is no danger of the bodys rejection of Fetal Stem Cells due to the fact they are immune privileged. This means that you can give the cells to any patient without matching, use of immunosuppressive drugs and without rejection. This unique quality eliminates the need for drugs used to suppress the immune system, which can leave a patient exposed to serious infections.

With over 3000 patients treated, Stem Cell Of America has achieved positive results with a wide variety of illnesses, conditions and injuries. Often, in cases where the diseases continued to worsen, our patients have reported substantial improvements following the Stem Cell treatment.

Patients have experienced favorable developments such as reduction or elimination of pain, increased strength and mobility, improved cognitive function, higher tolerance for chemotherapy, and quicker healing and recovery.

To view follow up letters from patients, please visit the patient experiences page on our website.

All statements, opinions, and advice on this page is provided for educational information only. It is not a substitute for proper medical diagnosis and care. Like all medical treatments and procedures, results may significantly vary and positive results may not always be achieved. Please contact us so we may evaluate your specific case.

Go here to see the original:
Breakthrough Stem Cell Treatments, Stem Cell Therapy ...

April 20, 2017 07:00 ET | Source: David Steenblock, D.O. Inc.

SAN CLEMENTE, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- David Steenblock, an osteopathic physician based in San Clemente, CA, uses stem cells and other therapies to achieve significant and improved lifestyle outcomes for many stroke patients.

Many of our cases have demonstrated improved mobility for stroke victims who received stem cell therapy, along with other therapies, including chelation and hyperbaric oxygen, says Dr. Steenblock.

One patient who suffered a stroke several years ago, came to Dr. Steenblocks clinic to undergo the full stroke program. This included EDTA chelation, a procedure that removes heavy metals from the blood, and hyperbaric oxygen therapy, along with stem cells from his bone marrow to effect healing and restoration.

After having the bone marrow stem cells, the patients eyesight improved, and both of his knees, which hadnt been working well, were back to functioning almost normally. In addition, his hip joint went back to normal function and he believes his balance when walking has improved tremendously.

The EDTA Chelation Therapy, a treatment used to remove heavy metals from the blood, was used with hyperbaric oxygen, which can lead to significant neurologic improvements for stroke patients.

Dr. David Steenblock is a leading-edge physician in many fields of medicine, from stroke care, to acute brain trauma, to generative and cell-based medicine in the treatment of ALS, Cerebral Palsy and other chronic and degenerative diseases. For more information about Dr. Steenblocks work in stem cell therapies, visit http://www.stemcellmd.org

Related Articles

David Steenblock, D.O. Inc.

San Clemente, California, UNITED STATES

David Steenblock, D.O. Inc. Logo

LOGO URL | Copy the link below

Formats available:

Original post:
David Steenblock, D.O., Uses Stem Cells and Other Therapies for ... - GlobeNewswire (press release)

The Husaini Haematology and Oncology Trust will soon provide facilities of bone marrow transplant and stem cell therapies at its newly established Blood Transfusion Centre and Thalassaemia Centre that was inaugurated by the city director health on Tuesday.

Speaking at the inaugural ceremony, Karachi director health Dr Muhammad Toufique urged the trust officials to share the data of patients undergoing blood transfusions, stem cell therapies and bone marrow transplant.

He said the data would help the Sindh government formulate a plan to establish more such facilities in the future. In addition to the blood screening and storage facilities, the centre is providing blood transfusion service to children suffering from genetic blood disorders as well as diagnostic services related to blood disorders.

This is a state-of-the-art blood transfusion and thalassaemia centre where bone marrow transplant and stem cell therapies would be started very soon, said a renowned haematologist associated with the Husaini Blood Bank, Dr Sarfraz Jaffery, at the inaugural ceremony of the blood transfusion and thalassaemia centre located at Qalandaria Chowk, North Nazimabad.

The head office of the Husaini Haematology and Oncology Trust is equipped with a diagnostic lab, blood bank having storage capacity of around 3,000 blood bags and blood transfusion centre for thalassaemic patients while its management is also planning to introduce bone marrow transplant and stem cell therapy services at the same facility in the near future.

Felicitating the trust officials, the city director health vowed to support them in their services. He said the government was also striving hard for provision of safe blood to thalassaemic children and other patients.

Dr Toufique hoped that institutions like Hussaini would come forward to support the government in establishing such centres in the province. Talking to journalists, the director health said steps were being taken to control the outbreak of Chikungunya in the city.

He said the health department was in contact with the municipal authorities to start fumigation in various areas of Karachi to eliminate the mosquitoes and prevent people from mosquito-borne diseases, including dengue and Malaria.

The Sindh government was planning to merge the Malaria and Dengue Prevention and Control Cells under one project director, who would be utilizing all the resources to eliminate the mosquitoes that were responsible for the deadly infectious diseases in the province, he added.

I would also urge people to take precautionary measures, prevent themselves and their children from mosquitoes by using repellents, improving sanitation conditions in their residential areas and adopt other preventive measures to protect themselves against the mosquitoes, he advised.

Earlier, speaking at a workshop on thalassaemia management held at the same place, noted haematologists of the country stressed the need for promoting the culture of prevention from diseases in the country.

They called for the implementation of laws regarding thalassaemia screening, saying that both the government and private sector could not treat the increasing number of thalassaemic patients.

Senior haematologist from Lahore, Prof Dr Jovaria Mannan, urged the doctors and researchers to use latest research methods in the field of haematology.

More:
Husaini trust plans to perform bone marrow transplants, stem cell therapy - The News International

A Melbourne woman is attempting to raise $170,000 for her sister to travel to one of the world's pre-eminent stem cell treatment facilities in an attempt to stop the fatal progression of Multiple Sclerosis.

Chantelle Baker was first diagnosed with MS in May, 2016. In a six month period, 79 lesions had developed on her brain.

"There is no medication to stop the progression of MS," Mrs Baker told A Current Affair.

Chantelle Baker, 41, is hoping to travel to Russia for stem cell treatment to stem the progression of Multiple Sclerosis (Source: A Current Affair)

Mrs Baker, her husband Dara, five-year-old daughter, Lilly, and younger daughter, Edie, are hostages to the hope that Russian doctors can achieve what Australia doctors cannot.

The cost is high, so Mrs Baker's sister, Maxine Parker, has set up an online fundraising campaign to raise the money on her sister's behalf.

"That's my job, I am her big sister," Ms Parker said.

"I have spent 17 years sharing the same bedroom with her growing up and there was no way I was going to let anything take her away from me and I still won't. I am determined to fight this all the way, side-by-side with her."

Mrs Baker's sister, Maxine Parker, has launched a crowd-funding campaign to pay for her sister's treatment in Russia (Source: A Current Affair)

But the cost is nothing compared to the regret the family would face if they didn't give it their all to get Mrs Baker to Russia for the ground-breaking treatment.

"I am scared of not being able to walk, I am scared of waking up one day and not being able to see my kids again because I have gone blind," Mrs Baker said.

"My worst fear is not remembering my children in four or five years' time."

Ms Parker said she would do anything to keep her sister active for her children (Source: A Current Affair)

NSW mother of two Nikki Tatum has just finished the treatment at the same stem cell clinic in Moscow that Mrs Baker is hoping to attend.

Ms Tatum is now back in Australia and will have to wait months before she knows if the therapy worked.

"I have just recently returned from to have HSCT (Hematopoietic Stem Cell Therapy) to hold the progression of my MS," Ms Tatum said in a video message to Mrs Baker.

"I just want to wish you luck for July and let you know that you have made the best choice. The doctors and nurses are just outstanding and you are definitely well looked after."

Mrs Baker, her husband and their children (Source: A Current Affair)

The video message affirmed to Mrs Baker that she was making the right decision.

"It definitely gives me hope. I know I am making the right decision and that is just verifying that I am," Mrs Baker said.

Mrs Baker's husband, Dara, agrees.

"We need to make it work. We need the treatment to work. But of course, I love her to death anyway," Mr Baker said.

Mrs Baker's family have set up a Facebook page where her journey can be followed, Chantelle Fights Multiple Sclerosis.

Nine Digital Pty Ltd 2017

Career news: Are you ticking the work-life balance box? - seek.com.au

Auto news:GM could sell Opel to Peugeot parent - caradvice.com.au

Auto news:Autonomous cars wont kill people, but they will take our jobs - caradvice.com.au

Auto news: What does the new American president mean for the auto industry? - caradvice.com.au

Auto news:A new Hyundai ute is now on the cards - caradvice.com.au

Auto news: Buying a new car? Here are 11 things you should consider first - caradvice.com.au

More here:
Melbourne woman travelling to Russia for ground-breaking MS stem cell treatment - 9news.com.au

Stem Cell Institute of America

The Stem Cell Institute of America trains physicians in your community on the amazing benefits of Stem Cells so they in turn are able to share their now extensive knowledge in this exciting subject with you. These Physicians have decided to educate local clubs, churches, business, organization in their community etc. on one of the most significant medical breakthroughs in natural medicine. Their purpose is to educate and answer questions on how you or someone you know can live a life without pain.

Chronic pain robs suffers of their quality of life and often leads to unnecessary pain medications and even depression. It is possible to turn the clock of time backwards and get your life back.

During our unique 2 hour presentation, you will learn everything there is to know about Stem Cells including how they work, the different types, where they work best, research studies and effectiveness.

Stem Cells are changing the lives of thousands across this great country for the better and our volunteers are fully trained by the Stem Cell Institute of America to present this amazing educational work shop to your local business, club, church, gym, organization, support group etc.

Using the most up to date techniques and research, The Stem Cell Institute of America has customized a presentation on this revolutionary medical breakthrough featuring strategic solutions for relief from many chronic pain and health issues. For instance, until recently, treatment options for people with chronic joint pain were limited to steroid injections and surgery that offer only short term or often-harmful outcomes.

Now, safe and effective treatments for knee, shoulders, hips, elbows, back and neck are available without harmful Side Effects or PAIN.

Regenerative Cellular Medicine works with the bodys natural ability to heal itself. Unlike treatments that simply address the symptoms, regenerative cell therapy actually promotes the natural process of repair in the body, assisting in restoring degenerated tissue.

Call us today to schedule our FREE informational seminars on the amazing benefits of Stem Cells and other advanced options, and learn more about the most significant medical breakthrough of the 21st century!

See the article here:
Stem Cell Institute of America | Stem Cell Therapy ...

Adipose-Derived Stem Cell Therapy

Scientists and doctors have made tremendous advances in moving regenerative medicine into the mainstream as a treatment for many diseases and disorders. Regenerative medicine takes advantage of our natural ability to heal ourselves by using the healthy adult stem cells found throughout the body. Laboratory and clinical research has shown that it is possible to use adult stem cells to restore lost, damaged or aging cells to effectively regenerate tissue and provide some patients with an alternative to surgery. Regenerative therapies are showing promise in orthopedic medicine, wound care, nerve restoration, and a variety of cardiovascular, neuromuscular, and autoimmune conditions.

Adult stem cells were discovered over 40 years ago when researchers found that cells derived from bone marrow had the ability to form various tissues. Adult stem cells are early stage cells that, under the right conditions, are capable of developing into other types of cells and hold the potential to regenerate damaged tissue.

AUTOLOGOUS ADULT STEM CELLS (ASCS) are being used to treat many types of chronic pain and degeneration. Currently doctors are treating shoulder, knee, hip, and spine degeneration, in addition to soft tissue (muscle, tendon, ligament) and other bone related injuries.

The first step is to determine if you are a good candidate for an adult stem cell procedure. Your physician will want a history of your injury and a physical examination along with any x-rays, and an MRI. While stem cell therapy maybe appropriate for certain conditions, it is not applicable for every condition. However, it is has proven to be a viable option for several individuals suffering from pain. Good candidates for adult stem cell treatment usually are:

Every patient is different, the success of the stem cell therapy is dependent on the severity of your condition and your bodys response to stem cell therapy.

Overview of the Procedure

An adult stem cell procedure harnesses and amplifies the bodys natural mechanism for healing and anti-inflammation. Once you have been identified as a good candidate for the procedure, a member of our team will review the procedure with you and answer any questions that you may have. A brief overview of the procedure is below:

Once the procedure is complete, our staff will allow you to rest and will create a customized personal rehabilitation program for recovery. We will either ask you to come back for a few post-operative appointments or follow up with you by phone, email, or mail so we can track you healing progress.

Potential Applications

Frequently Asked Questions (FAQs)

Q: What are adult stem cells?

A: Adult stem cells are unspecialized or undifferentiated cells, capable of two processes: self-renewal and differentiation. They are vital to maintaining tissues in the body such as internal organs, skin, and blood.

Q: What is Regenerative Medicine?

A: Regenerative Medicine is a new and advancing scientific field focused on the repair and regeneration of damaged tissue utilizing stem cells.

Q: What is the difference between adult stem cells and embryonic stem cells?

A: Adult stem cells are found in mature adult tissues including bone marrow and fat, while embryonic stem cells (ESCs) are not found in the adult human body. ESCs are obtained from donated in vitro fertilizations, which raises many ethical concerns. Because ESCs are not autologous, there is a possibility of immune rejection. Adult stem cells do not raise ethical issues nor pose any risks for immune rejection.

Q: Does Dr. Youm use embryonic stem cells in clinical procedures?

A: No, Dr. Youms approach to cell therapy relies only on autologous adult stem cells isolated from the patient during surgery. He does not participate in embryonic stem cell research or use embryonic stem cells in clinical applications.

Q: Are there ethical issues associated with harvesting adult stem cells?

A: No, adult stem cells do not raise ethical questions as they are harvested from the patients body.

Q: Are there cancer-causing risks associated with adult stem cell treatments?

A: No. Where embryonic stem cells have been shown to form teratomas (germ cell tumors), there is no data that suggests adult stem cells have the same potential to promote the development of tumors.

Q: Where do adult stem cells come from?

A: In adults, stem cells are present within various tissues and organ systems, the most common being bone marrow and adipose or fat tissues. Other sources include the liver, epidermis, retina, skeletal muscle, intestine, brain, placenta, umbilical cord and dental pulp.

Q: How does Dr. Youm obtain adult stem cells for use in cell treatment?

A: Dr. Youm currently has a system that uses adult stem cells from bone marrow and these stem cells are obtained through aspiration during your procedure.

Q: How are adult stem cells used in surgical procedures?

A: Adult stem cells are used to treat patients with damaged tissues due to age or deterioration. During a procedure, stem cells are isolated from the patient, concentrated and delivered back to the site of injury to assist in the healing process.

Q: Are there different types of adult stem cells?

A: Yes, there are many types of adult stem cells found in the body, which have variable differentiation potentials. The adult stem cells that aid in the repair of damages tissue are multipotent, mesenchymal stem cells. These are located in bone marrow and adipose (fat) tissue.

Q: Are the harvested adult stem cells expanded in a laboratory setting prior to delivery back to the patient?

A: No, Dr. Youm does not use in vitro expansion. The cells are harvested, processed in the operating room and delivered back to the patient at point of care.

Q: How do stem cells know what type of tissue to develop into?

A: The differentiation of stem cells is dependent on many factors, including cell signaling and micro-environmental signals. Based on these cues, stem cells are able to develop into healthy tissue needed to repair damaged tissue. For example, multipotent stem cells delivered to damaged bone will develop into bone cells to aid in tissue repair. The exact mechanism of lineage-specific differentiation is unknown at this point.

Q: Will my body reject the stem cells?

A: No, adult stem cells are autologous and non-immunogenic.

Q: Is stem cell therapy safe?

A: Yes, and ask your doctor what clinical studies have been done to show that stem cells are safe and effective.

Q: Where are stem cells currently being used?

A: Stem cells are currently being used in both laboratory and clinical settings. Laboratories are using human and animal derived stem cells to conduct in vitro studies as well as in vivo studies with small and large animals. Autologous adult stem cells are currently being used in hospitals and clinics during surgery to aid in the repair of damaged tissues.

Q: How long will the stem cells last?

A: It will depend on your injury, the area that is treated and your response to the therapy.

Q: What is the recovery like after a stem cell procedure?

A: If you have a joint injection, you typically can go back to work. It is advised to limit load bearing activities for at least 2 weeks. If you had disc injections, you should take it easy for a few days. Non-steriodal, anti-inflammatory medications (NSAIDS) should be withheld for 72 hours pre-procedure and one week after the procedure.

Q: What is the difference between autologous and allogeneic cells?

A: Autologous cells are taken from the same patient, typically at point-of-care. Allogeneic cells are taken from another patient and are often manipulated before they are given to another patient.

Q: Why use adult stem cell therapy rather than pharmaceuticals or genetic treatments?

A: Adult stem cells are from the body and generate natural proteins and therapeutic biochemicals, decrease inflammation, are anti-bacterial, and recruit other cells to heal the injured site. Pharmaceutical treatments only provide drugs with minimally effective dosages that may cause unwanted side effects. Over dosage can be dangerously toxic or even carcinogenic. Genetic therapy is still unproven and serious concerns exist about it causing cancer due to genetically manipulated cells.

Q: What is the difference between autologous and allogeneic cells?

A: Autologous cells are taken from the same patient, typically at point-of-care. Allogeneic cells are taken from another patient and are often manipulated.

Q: How much will it cost?

A: Most insurance will not cover stem cell procedures. Ask your doctor for payment options

The use of Stem cells in Hip Therapies

The use of Stem cells in Knee Therapies

The use of Stem cells in Shoulder Therapies

You will need the Adobe Reader to view and print these documents.

Read the original post:
Stem Cell Therapy New York City | Regenerative Medicine ...

NAVI MUMBAI: A forum group in Navi Mumbai conducted a question and answer session at Vashi to clear that there is no proof of stem cell therapy cure for autism. Around 100 parents of autistic children were part of the session held at Sunshine Autistic School in Vashi organised by the Forum for Autism group on Saturday. Guest speaker Dr Tatyana Dias, a PhD in neurobiology from the University of Edenburgh, UK, said, "All traditional therapies like occupational therapy, speech Therapy and special education are evidence-based which means they have been proved to be effective through immense research and practice. Whereas stem cell therapy is in research stage, its effectiveness is strongly doubted, even its practice is banned in many countries and if practised, it is done in labs and under strict regulations. In India at present there is no particular body or law to regulate stem cell research." Babita Raja, secretary, Forum for Autism, said, "Parents run from pillar to post for their children's treatment. We are hoping that this awareness programme would help them in deciding what they want to try."

Follow this link:
'No proof that stem cell therapy can cure autism' - Times of India

For the past five decades pharmaceutical drugs like levodopa have been the gold standard for treating Parkinsons disease. These medications alleviate motor symptoms of the disease, but none of them can cure it.

Now a study from the Karolinska Institute in Stockholm shows it is possible to coax the brains own astrocytescells that typically support and nurture neuronsinto producing a new generation of dopamine neurons.

The reprogrammed cellscould alter the course of Parkinsons, according to the researchers. You can directly reprogram a cell that is already inside the brain and change the function in such a way that you can improve neurological symptoms, says senior author Ernest Arenas, a professor of medical biochemistry at Karolinska.

Directly converting astrocytes already present in patients brains could eliminate the need to search for donor cells[and the treatment may] be less likely to cause side effects compared with current drugs. This is like stem cell 2.0. Its the next-generation approach to stem cell treatments and regenerative medicine, says James Beck, vice president and chief scientific officer, for the nonprofit Parkinsons Disease Foundation.

[Read the original study]

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Cell Therapy 2.0: Reprogramming the Brains Own Cells for Parkinsons Treatment

For more background on the Genetic Literacy Project, read GLP on Wikipedia

Read this article:
Parkinson's stem cell therapy 2.0: New treatment coaxes the brain to repair itself - Genetic Literacy Project

Mumbai: Regenerative Medical Services Pvt. Ltd on Wednesday said that the Drug Controller General of India (DCGI) recently approved its stem cell-based therapy to treat cartilage defects.

Chondron, its cartilage repair procedure, uses the bodys own cartilage cells that are cultured, multiplied and implanted into the patients damaged joint leading to new cartilage regeneration and avoiding the need for early joint replacement. This is the first stem cell-therapy product to be approved in India.

We are creating new age cartilage regeneration procedure which optimizes the chances of healing due to the use of the bodys own cells. We will tie up with hospitals to promote it; we have received interest from around 200 hospitals, chief executive officer and managing director Yash Sanghavi said.

The company has capacity to culture 1,000-1,200 patient samples annually, which it plans to enhance to 10,000-12,000 samples in next three years, chief scientific officer Satyen Sanghavi, said.

The Mumbai-based company, started in 2009, has invested around Rs70-75 crore on development of Chondron and conducted clinical trials on 350 patients. It is looking to raise funds for capacity expansion and marketing of the cell therapy.

We are looking to raise Rs40-50 crore through equity dilution and have already appointed bankers, Sanghavi said. The treatment, he said, is likely to cost around Rs2 lakh, which is almost the same or slightly lower than the price of a knee replacement surgery.

First Published: Wed, Apr 12 2017. 09 11 PM IST

Excerpt from:
DCGI approves Regenerative Medical's stem cell therapy for cartilage defects - Livemint

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured 920,000 from the British governments Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion.

A resulting product could have an enormous impact if a relatively low-cost, mass production system can be developed, as there is a huge need for ready supplies of blood.

The company is based at the open innovation Bioscience Catalyst campus in Stevenage in the UK,and will work in collaboration with stem cell scientists at the University of Edinburgh to develop the science.

Over 90 million blood transfusions are carried out worldwide each year, but alternative sources to donor-derived blood are urgently needed to meet rising demand.

However there are huge technical hurdles to overcome.

Dr Yen Choo

Scientists have shown that pluripotent stem cells can be used to make red blood cells in the laboratory, however as is often the case with stem cell derived products, the process is costly, inefficient and gives rise to many immature cells, preventing the therapy from progressing to clinical trials, commented Dr Yen Choo, Executive Chairman of Plasticell.

There is a need to secure a safer supply of blood products, especially in developing countries where there is a higher risk of transfusion-transmitted infection. However this is also a global issue, as supply chains solely reliant on human donors remain vulnerable to newly emerging diseases.

The company will use its patented CombiCult system, a combinatorial stem cell screening technology, to greatly improve the manufacturing process. The work will focus on the early stages of stem cell differentiation into hematopoietic progenitors that give rise to fully functional red blood cells.

The project is part of Plasticells hematopoietic cell therapy portfolio, which includes the expansion of umbilical cord- and bone- derived hematopoietic stem cells, and the manufacture of blood platelets and immune cells for oncology applications.

Over the past decade Innovate UK (formerly the Technology Strategy Board) has chosen Plasticell to deliver stem cell R&D projects valued at around 10 million, half of which were focused on the hematopoietic system.

There are a number of other research groups working on the challenge around the world. Another UK project is the NovoSang consortium, which began giving stem-cell derived red blood cellsto volunteers intrials last year.

Plasticell also has a pipeline of therapeutics using hematopoietic stem cell therapy, focusing on anaemia and thrombocytopenia, cancer immunotherapy and diabetes/obesity.

Dr Yen Choo is also chief executive of Progenitor Therapeutics, a spin-out which aims to develop drugs to regenerate specific tissues of the human body in response to injury, disease or ageing.

Progenitor Therapeutics has backing from SR One, the corporate venture arm of GSK, though Dr Choo has stressed that the company has so far been built up with a minimal amount of angel and institutional equity investment of around 10m ($12.5m).

More here:
Plasticell gets funding to develop blood substitute from stem cells - pharmaphorum

Chronic pain is a problem that sadly affects most people within their lifetime. There are patients who fall into the category of not responding to noninvasive therapies but they decline or are not candidates for joint or spine surgery. Some clinicians are turning to autologous stem cell therapy and they are seeing benefits.

Evidence of the effectiveness of the pain relief seen by the therapy have been reported to be at least 50% in relative consistency in some correlational studies, meaning the treatments may be working fairly well for a number of patients. A significant number of results have been seen in patients as much as 3 years after the procedure is performed, meaning that recuperation is highly likely for all types of pain and injuries.

Promising application of stem cell therapy resides within the treatment of degenerative disc disorder, which affects millions of people within the United States. In 2015, Pettine, Murphy, Suzuki et al. found that by using autologous stem cells to treat discogenic low back pain, they were able to improve pain scores in 21 of 26 patients within their study. Rehydration of the discs in eight of twenty patients according to MRI in conjunction with sustained pain relief through 12 months represents promise for the use of this regenerative medicine approach (Pettine, Murphy, Suzuki et al, 2014). Results such as these are promising and are currently encouraging larger clinical trials in order to generalize results across a very extensive breadth of patients.

Teton Spine and Sports Pain Center utilizes stem cells for the treatment of:

Repeat treatment can be initiated after 6 months for optimal results for patients with severe symptoms.

Stem cells have been clinically and scientifically proven to effectively treat chronic and acute pain. Stem cells are the bodys master cells. They are undifferentiated cells that have the ability to transform into a variety of different cells, replace dying cells, and regenerate damaged tissue. Stem cells are derived from your own bodys bone marrow or fat deposit (adipose).

An alternative method for regenerative medicine is through allograft tissues (from a purified amniotic source). These tissues have a high concentration of collagens, structural proteins and growth factors that support healing. This immune-privileged tissue can have some advantages over other regenerative therapies. Speak with our physician about which regenerative medicine technique would be right for you and your injury.

Stem cell therapy is a very simple and safe outpatient procedure that is performed by a qualified physician. Its easy as 1, 2, 3!

Removal of bone marrow or fat tissue. If you choose to use amniotic stem cells, half the battle is already over.

Once a sample of your bone marrow or fat tissue has been obtained, the cells are isolated with a specialized centrifuge. If you decide to use amniotic stem cells, they are delivered to the doctors office ready for injection.

The stem cells are then carefully injected into the site where the injury exists and the healing and regeneration begins!

Two advantages of a stem cell injection over surgery are:

Most patients find themselves back in their daily routine the day after the procedure. Healing gradually happens over the course of 2-6 weeks and can continue for up to 12+ months.

If you havent already learned all the wonderful benefits of stem cell therapy, here they are listed out for you:

Stem cell therapy procedures can treat the following conditions (but not limited to):

If you don't see your condition, please contact us. You may still be a candidate for stem cell therapy.

Stem cells are harvested and concentrated from amniotic fluid, bone marrow, or fat to be re-injected directly into damaged or degenerated tissues. This procedure is performed on the same day for the patients convenience and stem cells are minimally altered so as to advance the healing process for each patient. Since cells are obtained from the patient and returned to the patient within a single surgical procedure in most procedures, there are no issues with immune rejection or increased risk of infection.

Continue reading here:
Stem Cell Therapy | Stem Cell Treatments | Idaho Falls ...

For the past five decades pharmaceutical drugs like levodopa have been the gold standard for treating Parkinsons disease. These medications alleviate motor symptoms of the disease, but none of them can cure it. Patients with Parkinsons continue to lose dopamine neurons critical to the motor control centers of the brain. Eventually the drugs become ineffective and patients tremors get worse. They experience a loss of balance and a debilitating stiffness takes over their legs.

To replace the lost dopamine neurons, scientists have begun investigating stem cell therapy as a potential treatment or even a cure. But embryonic cells and adult stem cells have proved difficult to harness and transplant into the brain.

Now a study from the Karolinska Institute in Stockholm shows it is possible to coax the brains own astrocytescells that typically support and nurture neuronsinto producing a new generation of dopamine neurons. The reprogrammed cells display several of the properties and functions of native dopamine neurons and could alter the course of Parkinsons, according to the researchers. You can directly reprogram a cell that is already inside the brain and change the function in such a way that you can improve neurological symptoms, says senior author Ernest Arenas, a professor of medical biochemistry at Karolinska. Previously, scientists had to nudge specialized cells like neurons into becoming pluripotent cells before they could develop a different kind of specialized cell, he says. It was like having to erase all the written instructions for how a cell should develop and what job it should do and then rewriting them all over again. But Arenas and his team found a way to convert the instructions into a different set of commands without erasing them.

By adding a cocktail of three genes and a small RNA moleculeNEUROD1, ASCL1, LMX1A and miR-218, respectivelythe researchers forced astrocytes to transform directly into dopamine neurons. In culture, once human astrocytes were successfully reprogrammed this way, they looked and acted just like normal midbrain dopamine neurons. The reprogrammed cells grew axons, the long fibers that make connections with other neurons, fired electrical signals and released dopamine.

In mice, researchers first destroyed dopamine neurons in one part of the brain to produce a model of Parkinsons. Then they injected the cocktail of genes into the brain and observed the mice as they walked on a tiny treadmill. Within five weeks the mice began to walk straighter, their movements were more coordinated and their posture was improved.

The results, which were published in Nature Biotechnology today, open the door to a novel therapeutic approach for Parkinsons. Directly converting astrocytes already present in patients brains could eliminate the need to search for donor cells as well as avoid the risk of immunosuppression of transplanted cells. The treatments would also produce proteins involved in normal cellular processes and may therefore be less likely to cause side effects compared with current drugs. This is like stem cell 2.0. Its the next-generation approach to stem cell treatments and regenerative medicine, says James Beck, vice president of scientific affairs, for the nonprofit Parkinsons Disease Foundation who was not involved with the research. An estimated one million Americans and more than 10 million people worldwide live with Parkinsons. Replacing their lost dopamine neurons with reprogrammed brain cells could make management of their motor symptoms much easier, he notes. Instead of having to take eight pills or more every day in the later stages of the disease, people could reduce the amount of medication they have to take, maybe even down to zero.

But there are some caveats: Unfortunately, this is not going to halt the course of Parkinsons, Beck warns. If patients lose more dopamine neurons as the disease progresses, scientists or physicians may have to repeat the process of reprogramming replacement cells. And the disease often affects more than just dopamine neurons. There is a whole host of nonmotor symptoms that accompany Parkinsons, including cognitive impairment, depression, gastrointestinal complications and autonomic dysfunction. Motor improvement is only half the battle, according to Beck.

Researchers need to ensure the cocktail of added genes is standardized and produces robust cells in further tests. They will also need to verify that the process does not change other cells in the brain before it is ready for human clinical trials. Only a few small fetal and stem cell graft trials have been conducted so farand with mixed results, Beck said. But although this direct-reprogramming technique is being developed in parallel to stem cellbased therapies, it could be instructive as well as improve from clinical trials, eventually replacing stem cell therapy in the next decade, he adds. This is an insight into what the future of Parkinsons treatment holds.

Read this article:
Cell Therapy 2.0: Reprogramming the Brain's Own Cells for Parkinson's Treatment - Scientific American

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

The study presents reliable qualitative and quantitative insights into:

The regional analysis covers:

The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.

Highlights of the report:

Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.

Read more:
Stem Cell Therapy Market - Worldwide Industry Scope, Size ...

April 6, 2017 -- A stem cell treatment for autism shows promise, according to a new study, but the investigators and other experts emphasize that the therapy is still in the early stages and much more research is needed.

The Duke University study included 25 children, ages 2-6, with autism and assessed whether a transfusion of the youngsters' own umbilical cord blood containing rare stem cells would help treat their autism, CNN reported.

Behavioral improvements were reported in 70 percent of the patients, according to the study in the journal Stem Cells.

A second, larger trial is now underway and the researchers hope they will find a long-term treatment for autism, CNN reported.

Some experts say many unanswered questions remain and the study authors agree much more work needs to be done. This initial trial was a safety study, meaning doctors and the children's families knew the therapy was being administered and there was no comparison between treated and non-treated children.

"Some children, who were not speaking very much, had big increases in their vocabulary and their functional speech," study author Dr. Joanne Kurtzberg, head of the Robertson Clinical and Translational Cell Therapy Program, told CNN.

"Many children were able to attend to play and have meaningful communication in a way that they weren't before. Some children had less repetitive behaviors than they did when they came onto the study," Kurtzberg said.

"The study was very encouraging. We did see positive results. However, it did not have a comparison group, which is very important in establishing whether a treatment is actually effective," study author Dr. Geraldine Dawson, director of the Duke Center for Autism and Brain Development, told CNN.

WebMD News from HealthDay

The rest is here:
Stem Cell Therapy for Autism Shows Promise - WebMD